Lauren Dembeck, PhD, Author at Oncology Nurse Advisor

Lauren Dembeck, PhD, Author at Oncology Nurse Advisor https://www.oncologynurseadvisor.com Thu, 07 Mar 2024 14:43:17 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png Lauren Dembeck, PhD, Author at Oncology Nurse Advisor https://www.oncologynurseadvisor.com 32 32 Postoperative Radiotherapy Following Spinal Surgery Safe, Effective in Multiple Myeloma https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/multiple-myeloma-spinal-surgery-post-operative-radiotherapy-safe-effective/ Thu, 07 Mar 2024 14:10:00 +0000 https://www.oncologynurseadvisor.com/?p=117164 MRD Status Predicts Outcomes in Patients With Previously Untreated FL https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/follicular-lymphoma-mrd-minimal-disease-predict-outcome-treatment-risk/ Thu, 01 Feb 2024 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=116451 Midostaurin Plus Chemotherapy Is Well Tolerated in Adults With FLT3-Mutated AML, Irrespective of Age https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/acute-leukemia-aml-midostaurin-chemotherapy-treatment-risk/ Tue, 09 Jan 2024 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=115914 No Reduction in the Prevalence of Poor Physical Function in Survivors of ALL and NHL Seen Across Three Decades https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/poor-physical-function-acute-leukemia-survivors-prevalence-reduction/ Wed, 20 Dec 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=115034 The pitfall of self-reported stress levels is that the baseline stress for some people is so high, a cancer diagnosis doesn’t even register.

The pitfall of self-reported stress levels is that the baseline stress for some people is so high, a cancer diagnosis doesn’t even register.

Researchers sought to determine the prevalence of reduced function among survivors of ALL and NHL by treatment decade.]]> Frontline Chemo-Free Combination Shows Activity in Frail Older Patients With DLBCL https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/lymphoma-dlbcl-frontline-chemotherapy-combo-activity-older-patients/ Thu, 30 Nov 2023 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=114479 A patient’s frailty has been determined to be associated with a higher likelihood of developing toxi

A patient’s frailty has been determined to be associated with a higher likelihood of developing toxi

Researchers sought to determine whether a chemo-free combination of rituximab and lenalidomide in frontline therapy would be effective in older patients with DLBCL.]]> Inconsistent Use of PET-CT, Deauville Scores Seen in Advanced-Stage Classic Hodgkin Lymphoma in Community Oncology Settings https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/hodgkin-lymphoma-inconsistent-use-pet-vt-deauville-scores-treatment-risk/ Fri, 06 Oct 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=111207 $In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma.$ Researchers sought to determine the use of PET-CT scans and Deauville scores for patients with stage III/IV cHL undergoing frontline therapy in a community oncology setting.]]> CAR‑HEMATOTOX Score Shows Prognostic Utility for CAR‑T Therapy in Relapsed/Refractory Multiple Myeloma https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/multiple-myeloma-car-hematotox-score-prognostic-utility-cart-therapy/ Fri, 01 Sep 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=110293 CAR T-cell therapy

Researchers sought to determine whether the CAR‑HEMATOTOX score would have prognostic value for both toxicity and treatment response in patients with R/R MM receiving CAR-T therapy.]]> Homoharringtonine-Based Induction Therapy May Reduce Post-Transplant Relapse in Pediatric AML https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/acute-leukemia-aml-homoharringtonine-induction-therapy-post-transplant-hsct/ Fri, 11 Aug 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=109815 Stem cells

Researchers sought to determine whether homoharringtonine-based induction therapy would lower disease recurrence in pediatric patients with AML after HSCT.]]> Superior PFS Seen With Nivolumab vs Brentuximab Vedotin in Advanced-Stage cHL https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/chl-lymphoma-superior-survival-pfs-nivolumab-brentuximab-treatment-risk/ Tue, 20 Jun 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=108609

Researchers sought to determine whether nivolumab would improve PFS compared with brentuximab vedotin in patients with advanced-stage cHL.]]> Comparable Early Outcomes Seen With Axi-Cel in Real-World, Trial Settings for Relapsed/Refractory Follicular Lymphoma https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/follicular-lymphoma-axicel-real-world-trials-early-outcomes-zuma-trial/ Thu, 15 Jun 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=108586 Nurse writing in chart beside patient in hospital bed.

Nurse writing in chart beside patient in hospital bed.

Researchers sought to determine whether axi-cel would have efficacy and safety for treating follicular lymphoma in a real-world setting compared with the ZUMA-5 trial.]]>